Osmetech looks for a US marketing partner:
This article was originally published in Clinica
Executive Summary
Osmetech, a UK company developing technology to diagnose disease from analysis of the scent given off, says it has completed clinical trials to detect urinary tract infection and estimates the test could win US FDA approval by the autumn. Osmetech says that it now seeks a large US diagnostics company to commercialise the test. Osmetech has recently appointed a new chief executive, James White, to replace Giap Wang Chong, who now takes a non-executive role. Osmetech saw increased losses for its first six months, up to £2.1 million ($3 million) compared with £1.7 million for the same period last year.